AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02420015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy
Description: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
Study NCT02420015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
Study NCT02420015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
Study NCT02420015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
Study NCT02420015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral smoking cessation counseling
Description: Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
Study NCT02420015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral smoking cessation counseling
Description: Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
Study NCT02420015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
Study NCT02420015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay Quit Coach
Description: Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
Study NCT02420015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS text messaging
Description: Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
Study NCT00647959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Tablets, 150mg
Description: 150mg, single dose fasting
Study NCT00647959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adoxa Tablets 150 mg
Description: 150mg, single dose fasting
Study NCT00528450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study NCT00528450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study NCT00528450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Study NCT03452163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMD-200
Description: the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception.
Study NCT03452163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitor
Description: An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
Study NCT01976741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) oral solution
Description: Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
Study NCT01976741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) oral tablet
Description: Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
Study NCT01976741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877) 800 mg BID
Description: Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
Study NCT06170099 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: irradiation with LLLT by the following regimen 0, 3, 7 and 14 from the activation of the bony supported Distal Jet and then every 15 days till completion of distalization
Study NCT06170099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bonny supported distal jet
Description: distal jet distalizing appliance is supported on two paramedian screw
Study NCT06170099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bonny supported distal jet
Description: distal jet distalizing appliance is supported on two paramedian screw
Study NCT03446404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standing Computed Tomography
Description: Provides weight bearing 3D view of knees.
Study NCT03725618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever 17DD Vaccine
Description: live attenuated vaccine based on the 17DD strain
Study NCT01146795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
Study NCT01146795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
Study NCT01146795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
Study NCT04413617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 400 mg
Study NCT04413617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 100 mg
Study NCT04413617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 11 mg
Study NCT04712630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-incised papila surgical approach without grafting biomaterial
Description: Periodontal reconstructive surgery
Study NCT04712630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-incised papila surgical approach with grafting biomaterial
Description: Periodontal reconstructive surgery
Study NCT03372681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isoperistaltic Billroth II + Braun anastomosis
Description: Laparoscopic distal gestrectomy will be applied with Isoperistaltic Billroth II + Braun reconstruction
Study NCT03372681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antiperistaltic Billroth II + Braun anastomosis
Description: Laparoscopic distal gestrectomy will be applied with antiperistaltic Billroth II + Braun reconstruction
Study NCT02039024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F- DTBZ
Description: During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).
Study NCT02023697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Study NCT00845897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: 200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
Study NCT00845897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
Study NCT01802138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated T lymphocyte
Description: intravenous dripping of 200 ml (10\^9\~2\*10\^10 lymphocytes) for 1 hour.
Study NCT02009280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of anesthesia: Propofol
Description: Maintenance of anesthesia with the propofol
Study NCT02009280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of anesthesia: Sevoflurane
Description: Maintenance of anesthesia with the sevoflurane
Study NCT01776216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy diet
Description: During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
Study NCT01776216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
Study NCT02340637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Kids
Description: The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
Study NCT02340637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual
Study NCT03739125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Study NCT03739125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Study NCT00776516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study NCT00776516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: oral
Study NCT04685889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device.
Study NCT04106076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART123
Description: Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
Study NCT00887211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
Study NCT00887211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
Study NCT03865381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Onduo App
Description: The Onduo App is a software application which tracks data relevant to diabetes care, such as, but not limited to, medication, meal logs and glucose readings, and activity data. The Onduo App connects wirelessly to a Care Team Console through the Internet. The Onduo App may also connect wirelessly to commercially available FDA-regulated (i.e., cleared and approved) medical devices and non-medical devices through the subject's Smartphone.
Study NCT04302909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: focused extracorporeal shock wave therapy
Description: 40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
Study NCT04302909 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham focused extracorporeal shock wave therapy
Description: 40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
Study NCT04302909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: night splint
Description: 40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
Study NCT04302909 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: night splint
Description: 40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
Study NCT00652106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
Description: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
Study NCT00652106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
Description: Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
Study NCT00652106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.2% ophthalmic solution
Description: Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
Study NCT03306316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Prebiotic experimental group
Study NCT03306316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose Control
Description: Dextrose Control
Study NCT04013659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation
Description: After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED
Study NCT01377337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium bicarbonate
Description: 1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion).
Study NCT01377337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: 1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion).
Study NCT03815266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: transcranial Direct Current Stimulation (tDCS) is device which consist in setting up an electrode on the skull of the patient to deliver the low intensity current.~Patient will have transcranial Direct Current Stimulation (tDCS) at each session and at the same time of Computerized Mirror Therapy (CMT).
Study NCT03815266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computerized Mirror Therapy (CMT)
Description: Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3). Patient will have Computerized Mirror Therapy (CMT) at each session and at the same time of transcranial Direct Current Stimulation (tDCS).
Study NCT03815266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tolerance Assessment Questionnaire
Description: The Tolerance Assessment Questionnaire will be completed at the end of each session.
Study NCT03815266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ashworth's scale
Description: Ashworth's scale evaluates the resistance to stretching. This test will be completed before the start of the program, at the end of the program and one month after.
Study NCT03815266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Frenchay arm test
Description: Frenchay arm test evaluates your abilities with the affected hand to perform several actions.~This test will be completed before the start of the program, at the end of the program and one month after.
Study NCT03815266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abilhand questionnaire
Description: Abilhand questionnaire evaluates your abilities to perform several activities in the daily life with your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after.
Study NCT03815266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer test
Description: Fugl-Meyer test evaluates your ability to perform different movements with all the joints of your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after.
Study NCT03815266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Goal Attainment Scaling (GAS)
Description: Goal Attainment Scaling (GAS) sets therapeutic goals with the patient before the start of the program.~These goals will be checked at the end of the program and one month after.
Study NCT01957046 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Laxative
Study NCT01063283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 intravenously over 10 minutes
Study NCT01063283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes
Study NCT01063283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 7.5 mg/kg
Description: Bevacizumab at 7.5 mg/kg intravenously over 90 minutes